Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis

Renal Cell ◽

Line Treatment ◽

Efficacy And Safety ◽

Single Center ◽

First Line ◽

4509 POSTER Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71140-0 ◽

2007 ◽

Vol 5 (4) ◽

pp. 301 ◽

Cited By ~ 8

Author(s):

R.J. Motzer ◽

M.D. Michaelson ◽

T.E. Hutson ◽

P. Tomczak ◽

R.M. Bukowski ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Prognostic Factors ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Efficacy and Safety of Sunitinib as First-Line Treatment in Patients with Metastatic Renal Cell Carcinoma: Systematic Review

Value in Health ◽

10.1016/j.jval.2016.03.1534 ◽

2016 ◽

Vol 19 (3) ◽

pp. A169

Author(s):

C Huerfano ◽

CP Niño ◽

F Davila ◽

JM Reyes ◽

JA Diaz

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.4609 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 4609-4609 ◽

Cited By ~ 10

Author(s):

M. E. Gore ◽

R. J. Jones ◽

A. Ravaud ◽

M. Kuczyk ◽

T. Demkow ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Dose Escalation ◽

Renal Cell ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors

BMC Cancer ◽

10.1186/s12885-016-3016-4 ◽

2017 ◽

Vol 17 (1) ◽

Cited By ~ 12

Author(s):

Hai-Liang Zhang ◽

Xi-Nan Sheng ◽

Xue-Song Li ◽

Hong-Kai Wang ◽

Zhi-Hong Chi ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Prognostic Factors ◽

Cell Carcinoma ◽

Retrospective Analysis ◽

Renal Cell ◽

Chinese Patients ◽

Line Treatment ◽

First Line ◽

A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma

European Urology ◽

10.1016/j.eururo.2021.03.016 ◽

2021 ◽

Author(s):

Irbaz Bin Riaz ◽

Huan He ◽

Alexander J. Ryu ◽

Rabbia Siddiqi ◽

Syed Arsalan Ahmed Naqvi ◽

...

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Meta Analysis ◽

Line Treatment ◽

First Line ◽

Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma

PharmacoEconomics ◽

10.1007/s40273-012-0006-5 ◽

2012 ◽

Vol 31 (1) ◽

pp. 15-24 ◽

Cited By ~ 21

Author(s):

Mary Kilonzo ◽

Jenni Hislop ◽

Andrew Elders ◽

Cynthia Fraser ◽

Donald Bissett ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES

Current Opinion in Urology ◽

10.1097/mou.0000000000000207 ◽

2015 ◽

Vol 25 (5) ◽

pp. 395-401 ◽

Cited By ~ 6

Author(s):

Manuela Schmidinger ◽

Janet Wittes

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

How does vaccine treatment compare with standard targeted therapy for first-line treatment of people with metastatic renal cell carcinoma?

Cochrane Clinical Answers ◽

10.1002/cca.2631 ◽

2019 ◽

Author(s):

Jane Burch ◽

Gustavo Villalobos

Keyword(s):

Renal Cell Carcinoma ◽

Targeted Therapy ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

Vaccine Treatment ◽

Efficacy and safety of immunological checkpoint inhibitors combined with anti-angiogenic drugs in first-line treatment of metastatic renal cell carcinoma: a systematic review and meta-analysis

Translational Andrology and Urology ◽

10.21037/tau-20-969 ◽

2021 ◽

Vol 10 (1) ◽

pp. 300-309

Author(s):

Yingwei Xie ◽

Zhiliang Chen ◽

Qiyu Zhong ◽

Yuqing Chen ◽

Wentai Shangguan ◽

...

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Checkpoint Inhibitors ◽

Meta Analysis ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

PCN5 PHARMACOECONOMIC ANALYSIS OF SORAFENIB AND SUNITINIB FOR FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) COMPARED WITH COMBINATION THERAPY OF BEVACIZUMAB, GEMCITABINE, AND CAPECITABINE (BGC) AT A LARGE CANCER CENTER

Value in Health ◽

10.1016/s1098-3015(10)68916-4 ◽

2007 ◽

Vol 10 (3) ◽

pp. A124 ◽

Cited By ~ 1

Author(s):

WD Smith ◽

R Arbuckle

Keyword(s):

Renal Cell Carcinoma ◽

Combination Therapy ◽

Cell Carcinoma ◽

Renal Cell ◽

Pharmacoeconomic Analysis ◽

Cancer Center ◽

Line Treatment ◽

First Line ◽